NBIX News and Press, Neurocrine Biosciences Inc. From 02/04/21

Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results Total Annual Revenues in 2020 Grew 33% to Over $1 Billion INGREZZA® (valbenazine) Full Year 2020 Net Product Sales and TRx Both Grew 32% to $993 Million and Approximately 175,700 TRx, Res...

Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to announce Q4 earnings results on Thursday, February 4th, after market close.The consensus EPS Estimate is $0.91 (-13.3% Y/Y) and the consensus Revenue Estimate is $260.67M (+6.8% Y/Y).Over the last 2 years, NBIX has beaten EPS estimates 63% ...

[[AINV]], [[ATVI]], [[BHE]], [[BILL]], [[COLM]], [[CPT]], [[CSL]], [[DECK]], [[DLX]], [[DXC]], [[ENVA]], [[ESS]], [[EXPO]], [[F]], [[FLT]], [[FTNT]], [[FTV]], [[GILD]], [[GPRO]], [[HIG]], [[HUBG]], [[KN]], [[LESL]], [[LGF.A]], [[LPLA]], [[MCHP]], [[MPWR]], [[MSI]], [[MTD]], [[MTX]], [[NBIX]],...

Neurocrine has chosen to terminate development of NBIb-1817, the gene therapy for Parkinson's it acquired through its partnership with Voyager. Ingrezza sales have been knocked off stride by COVID-19, and it remains to be seen how quickly the company can regain the sort of growth that...

Voyager Therapeutics (VYGR) has lost ~12.8% today after BTIG downgraded the stock to neutral from buy, noting the multiple clinical holds faced by the company. The price target of $6.50 per share implies a ~18.8% downside to the previous close.Even though the analyst Thomas Shrader ...

Voyager Therapeutics (VYGR) said that its partner Neurocrine Biosciences (NBIX) had given it a notice of  termination of the Parkinson’s disease portion of their collaboration agreement, effective August 2, 2021.Voyager is evaluating the complete financial impact of the termi...

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results Conference Call and Webcast Scheduled for Thursday, February 4 PR Newswire SAN DIEGO , Jan. 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc...

VYGR's Parkinson's Disease asset partnered with Neurocrine has been put on clinical hold by the FDA. The asset - and the company - has a complicated history of deal making and deal breaking. The clinical hold has put the company's future in question. For further details see:...

Neurocrine Biosciences (NBIX) updates on preliminary Ingrezza (valbenazine) sales for 2020, and key 2021 milestones.Q4 and FY20 Ingrezza net product sales are expected to be ~$240M and $993M, respectively.Ingrezza inventory adjusted net product sales for Q4 were ~$258M.FY20 total INGREZZA pre...

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales and Inventory Adjusted Net Product Sales of Approximately $240 Million an...